Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer
International Journal of Gynecology & Obstetrics · 2026
DOI: 10.1002/ijgo.70336 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Joshua S Cheruvathur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Women's Health Research Unit, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy.
Methods
A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Results
Overall, 54 patients were included, 23 (43%) treated by IP and 31 (57%) by IV chemotherapy. Median progression‐free survival (PFS) in the IP group was 39 months (95% confidence interval [CI] 34–44 months) versus 23 months (95% CI 18–28 months) in the IV group ( P = 0.294). The IP chemotherapy had superior OS compared with IV chemotherapy, with median OS not reached, versus 76 months (95% CI 37–115 months) for the IV group ( P = 0.075, hazard ratio 0.45, 95% CI 0.18–1.10). At 72 months, OS was 82% for the IP group versus 53% in the IV group. In a sensitivity analysis for Stage IIIc patients only ( n = 39), the median OS was 130 months (95% CI 86–174 months) in the IP group, compared with 56 months (95% CI 35–76 months) for the IV group ( P = 0.152). Toxicity profiles were similar in both groups, with no Grade ≥3 toxicity.
Conclusion
Stage III HGSOC patients treated with IP chemotherapy had significantly longer OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Health Research Unit, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Surgery, Division of Surgical Research, McGill University, Montreal, Quebec, Canada.
- JSS Medical Research, Montreal, Quebec, Canada.
ORCID-Profile: Gabriel Levin
Zitieren
APA
Cheruvathur, J. S., Levin, G., Ribeiro, R., Racovitan, F., Power, J., Zeng, X., Sampalis, J., & Gilbert, L. (2026). Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70336
Vancouver
Cheruvathur JS, Levin G, Ribeiro R, Racovitan F, Power J, Zeng X, et al. Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70336
BibTeX
@article{Cheruvathur2026,
author = {Cheruvathur, Joshua S and Levin, Gabriel and Ribeiro, Reitan and Racovitan, Florentin and Power, Joanne and Zeng, Xing and Sampalis, John and Gilbert, Lucy},
title = {Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer},
journal = {International Journal of Gynecology & Obstetrics},
year = {2026},
doi = {10.1002/ijgo.70336}
}
EUVIMED